Abstract Number: 151 • 2017 Pediatric Rheumatology Symposium
Severe Phenotype of Mevalonate-kinase Deficiency in the Czech Republic
Background/Purpose: Disease phenotype of mevalonate-kinase (MVK) deficiency (MKD) varies in relation to the extent of enzymatic activity reduction. It ranges from multi-organ involvement with fatal…Abstract Number: 1196 • 2016 ACR/ARHP Annual Meeting
AA Amyloidosis: An Evaluation of Epidemiology and Prevalence in the US and EU5 Countries
Background/Purpose: AA amyloidosis (AAA) is a rare, systemic form of amyloidosis, which mostly occurs secondary to chronic inflammatory conditions, predominantly systemic arthritides. AAA is characterized…Abstract Number: 1468 • 2014 ACR/ARHP Annual Meeting
Mechanism of Effectiveness of IL-6 Blockade for Reduction of SAA Production and Amyloid a Deposition in AA Amyloidosis Patients with RA
Background/Purpose AA amyloidosis is a serious complication of chronic inflammatory and infectious diseases resulting from the deposition of amyloid A protein. Serum amyloid A (SAA),…Abstract Number: 1207 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Tocilizumab In Patients With AA Amyloidosis Secondary To Familial Mediterranean Fever: A Single Centre Experience
Background/Purpose: The most frequent underlying diseases responsible for AA amyloidosis worldwide are rheumatoid arthritis, juvenile idiopathic arthritis and ankylosing spondylitis, while familial Mediterranean fever (FMF)…Abstract Number: 431 • 2012 ACR/ARHP Annual Meeting
Basic and Clinical Significance of Interleukin 6 (IL-6) in AA Amyloidosis with RA
Background/Purpose: Cytokine-induced hepatic serum amyloid A (SAA) is associated with the pathogenesis of AA amylodosis, a fatal disease with deposition of AA amyloid fibril on…
ACR Meeting Abstracts